JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
Last updated: 01 November 2019
In a recent trial, 80% of patients with (MRD)-positive acute lymphoblastic leukemia (ALL) who were treated with a drug called Blincyto (blinatumomab) achieved a complete response.Read more